Ramin Farzaneh-far
Chief Medical Officer at Capstan Therapeutics
Greater Boston
Overview
Work Experience
Chief Medical Officer
2024 - Current
Capstan Therapeutics is advancing cell engineering to develop therapeutics for a broad range of diseases.
Raised $340,000,000.00 from Bristol-Myers Squibb, Mubadala Capital Ventures, RA Capital Management, Eli Lilly & Company Foundation, Polaris Partners, Johnson & Johnson Innovation – JJDC, Sofinnova Investments, Perceptive Advisors, Leaps by Bayer and Pfizer Venture Investments.
Venture Partner
2020 - 2024
Executive Chairman
2020 - 2021
Chief Medical Officer
2016 - 2020
Ra Pharma is developing Cyclomimetics, a new drug class combining the properties and benefits of antibodies and small molecules.
Raised $226,933,082.00 from Rock Springs Capital, Morgenthaler Ventures, Amgen Ventures, Novo Ventures, RA Capital Management, New Enterprise Associates, Limulus Venture Partners, Lightstone Ventures and Novartis Venture Fund.
Vice President, Medical Research
2015 - 2016
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Raised $442,500,000.00 from BlackRock and Pharmakon Advisors.
Director, Clinical Research
2012 - 2015
Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
Raised $4,413,500,000.00 from Abingworth.
Assistant Professor of Medicine
2011 - 2012
Assistant Professor of Medicine
2009 - 2011
Fellow, Cardiovascular Medicine
2006 - 2009
Resident, Internal Medicine
2003 - 2006